{"organizations": [], "uuid": "e3aca9df027be6a6aaa33ced6d68b37065340992", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/healthNews", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-santhera-raxone/santheras-raxone-shows-no-efficacy-benefit-in-ms-study-idUSKBN1GH0ZL", "country": "US", "domain_rank": 408, "title": "Santhera's Raxone shows no efficacy benefit in MS study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-03-05T16:50:00.000+02:00", "replies_count": 0, "uuid": "e3aca9df027be6a6aaa33ced6d68b37065340992"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-santhera-raxone/santheras-raxone-shows-no-efficacy-benefit-in-ms-study-idUSKBN1GH0ZL", "ord_in_thread": 0, "title": "Santhera's Raxone shows no efficacy benefit in MS study", "locations": [], "entities": {"persons": [{"name": "santhera", "sentiment": "negative"}, {"name": "raxone", "sentiment": "none"}, {"name": "leber", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "norway", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "liechtenstein", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}, {"name": "iceland", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "santhera pharmaceuticals", "sentiment": "negative"}, {"name": "european union", "sentiment": "none"}, {"name": "european medicines agency", "sentiment": "none"}, {"name": "u.s. national institutes of health", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH (Reuters) - Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.\nRaxone, also known as idebenone, is Santhera’s lead product and is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for treatment of Leber’s hereditary optic neuropathy (LHON).\nBut efforts to expand its use have faltered, including in January when a key European Medicines Agency’s panel baulked at recommending it in Europe for Duchenne muscular dystrophy (DMD), despite an appeal by the company.\nThat rejection prompted a share drop of more than a third.\nThis latest MS study, sponsored by the U.S. National Institutes of Health, was completed by just 66 patients, something Santhera called out as a potential limiting factor in making a determination about its efficacy.\n“Clearly, the small sample size is a limitation when studying a therapeutic intervention in such a complex, relentlessly progressing neurological disease,” said\nChief Executive Thomas Meier in a statement.\nReporting by John Miller, editing by Louise Heavens\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T16:50:00.000+02:00", "crawled": "2018-03-05T12:08:47.009+02:00", "highlightTitle": ""}